Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, interventional, open-label, phase 1a/1b, single-center, clinical study to evaluate the safety and tolerability of NV-CoV-2 Oral Syrup and Oral Gummy (Chewable gel) for oral administration in healthy and mild to moderate COVID-19 adult human subjects

Next Previous
X
Search
Trial Profile

A prospective, interventional, open-label, phase 1a/1b, single-center, clinical study to evaluate the safety and tolerability of NV-CoV-2 Oral Syrup and Oral Gummy (Chewable gel) for oral administration in healthy and mild to moderate COVID-19 adult human subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NV CoV 2 (Primary) ; NV CoV 2 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Karveer Meditech

    • Most Recent Events

    • 08 Aug 2024 According to a NanoViricides media release, the Company is in the progress of completing a database audit of this trial and asked for an external technical audit which is in progress. Once the audits are completed, a data-lock will be effected and then the database will be analyzed statistically. Then a final Phase I clinical trial report will be prepared.
    • 30 Apr 2024 According to a NanoViricides media release, trial was closed and completed in Apr by the Drug Sponsor and licensee, Karveer Meditech, Pvt. Ltd., and the CRO, PristynCR. The decision to close the clinical trial with healthy subjects study completed was taken because diligent efforts to identify suitable COVID-19 participants for the clinical trials were met with a notable absence of positive cases at the designated clinical trial sites, despite addition of a 2nd site during Jan/Feb 2024
    • 30 Apr 2024 Status changed to completed as per NanoViricides media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top